Using coverage and claims data provides pharma a view of payer and prescriber behavior
Insufficient return on investment due to an underperforming launch is a thought that makes any pharma manufacturer shudder. Considering that about half of all products launched over the last 15 years have underperformed pre-launch consensus forecasts by more than 20%, companies must proactively plan their near- and long-term strategies to ensure financial losses remain a […]
How real-world evidence is impacting regulatory decision-making: 12 recent approvals based on RWE
Volume 2 Offering 12 new use cases of life sciences companies continuing to invest in RWD to advance product approvals before an FDA that is only becoming more accepting of RWE.
Clinical pathways: What are they, and how do they affect access?
By Lindsay Lorenzen VP of Solution Consulting, Norstella Pharma manufacturers working within oncology, and a few other select fields, face a unique challenge when bringing their therapies to market: clinical pathways. According to MMIT Pulse Analytics data, roughly 62% of U.S. oncologists are currently exposed to a clinical pathway. And of those using pathways, adherence […]
15 critical business questions keeping pharma leaders up at night
To ensure success in today’s evolving pharmaceutical marketplace, you need answers to critical business questions at each step of the drug development life cycle. Is your organization equipped to answer these burning questions? Business Development 1. Of all assets available, what asset has the highest potential and is most likely to give me the patient […]
Norstella SMEs reflect on the biggest stories of 2022 and the industry trends to come
Now that 2023 is upon us, now’s the time to gather some key intel from the past year: What did we learn from some of the biggest stories in life sciences? And how can we apply those learnings in the year ahead? To gain some perspective, we tapped SMEs from across the Norstella brands to […]
Improving market access: Are you making the most of real-world data?
By Lindsay Lorenzen VP of Solution Consulting, Norstella As drug and therapy innovation becomes more specialized and costs continue to rise, improving market access becomes more complicated. As the landscape evolves, pharma manufacturers must strategize accordingly to ensure a successful launch. Navigating the changing market access landscape is a common struggle for pharma manufacturers: One […]